Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience
- 5 November 2016
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (4) , e26265
Abstract
Background Adolescent and young adult (AYA) patients with very high risk sarcomas have poor outcomes and are in need of novel therapies. Procedure From January 2005 to February 2016, we retrospectively identified all AYA patients with relapsed or metastatic high-grade sarcomas, who were treated with at least one cycle of docetaxel (T), bevacizumab (A), and gemcitabine (G) (TAG ; T = 100 mg/m2 Day 8, A = 15 mg/kg Day 1, G = 1,000 mg/m2 Days 1 and 8). Results Fourteen patients, median age of 20 (15–30), received a total of 80 cycles of TAG, and were followed for a median of 83 months. Diagnosis included osteosarcoma (OST; 8), Ewing sarcoma (3), and soft tissue sarcoma (3). Five of 14 patients achieved clinical remission (CR), 3 had partial responses (PR), 3 had stable disease (SD), and 3 had progressive disease (PD). The median progression-free survival and overall survival were 7 and 19 months, respectively. The objective response rate (CR + PR) and tumor control rate (CR + PR + SD) were 57% and 79%, respectively, with two patients alive after 5 years; toxicities included thrombocytopenia, neutropenia, and capillary leak syndrome. Conclusions Our study builds on previous studies utilizing TAG in adult leiomyosarcoma (LMS) by focusing on AYA, non-LMS sarcomas, especially OST. Our experience suggests that TAG is well tolerated and has activity in very high risk sarcomas in AYA.Keywords
Funding Information
- Amanda Sarmiento Memorial Fund.
This publication has 45 references indexed in Scilit:
- Recent advances in osteosarcomaCurrent Opinion in Pharmacology, 2014
- Gemcitabine, Docetaxel, and Bevacizumab in Relapsed and Refractory Pediatric SarcomasJournal of Pediatric Hematology/Oncology, 2012
- Efficacy and Safety of Gemcitabine-Docetaxel Combination Therapy for Recurrent or Refractory High-grade Osteosarcoma in China: A Retrospective Study of 18 PatientsJapanese Journal of Clinical Oncology, 2012
- Targeted Therapy in Bone and Soft Tissue Sarcoma in Children and AdolescentsCurrent Oncology Reports, 2012
- Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomasPediatric Blood & Cancer, 2012
- Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcomaCancer, 2008
- Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002Journal of Clinical Oncology, 2007
- Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysisInternational Journal of Cancer, 2006
- Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treament With Gemcitabine Followed by Docetaxel in the Treatment of SarcomaJournal of Clinical Oncology, 2004
- Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of TaxolJNCI: Journal of the National Cancer Institute, 1991